Why it ranks
How the rank works- went through YCProgram · this site+4
A sum of public facts, not a judgement and not investment advice.
Competitors
| Company | Category | Status | Program |
|---|---|---|---|
| AI | Not stated | Seedcamp2024 | |
| AI | Active | YCW19 | |
| AI | Not stated | 500 Global2022 | |
| AI | Active | YCW15 | |
| AI | Active | YCW20 |
Adjacent
| Company | Category | Status | Program |
|---|---|---|---|
| Other | Not stated | EF2019 | |
| Pipedata AIShared: croAlchemist Class 36Not statedOther | Other | Not stated | AlchemistClass 36 |
| AI | Active | YCW25 | |
| Other | Public | YCW15 | |
| AI | Active | YCS26 |
Also from F26 in AI
All of F26Founders
- Alessandro HammondFounder/CEO
- Keanu ClarkFounder/CTO
About Nxtcure Labs
NxtCure Labs is an AI-native, full-stack CRO built to take therapeutics from discovery to market faster. We are reinventing medicine from lab to drug discovery. About 2 million Americans are diagnosed with cancer every year. Science has never moved faster, new immunotherapies, targeted drugs and cancer vaccines arrive every year. But roughly 90% of cancer drugs fail in clinical trials, and about 80% of trials run late. The breakthroughs exist. The way we test them is stuck in the last century. NxtCure is building autonomous clinical trials. Before a single patient enrolls, we run the trial thousands of times on digital twins. Each virtual patient is a system of coupled differential equations that track how a drug moves through plasma, tumor and heart, and how the tumor grows, shrinks or fights back. The parameters are fit to real trial data, so every twin behaves like real biology. Across thousands of simulations we can calculate the odds that a dose will hit its endpoints, and fix the protocol before it costs anyone time, money or hope. Then 13 AI agents run the trial. Each one owns a stage: drafting the protocol, ranking sites, pre-screening patients, forecasting drug supply, watching for adverse events, predicting dropout, cleaning data and writing the final report. As real data comes in, the twins update and flag problems weeks before a human would see them. In 2025, the FDA laid out how computer simulation can take its place. Soon a cancer drug will run through thousands of simulated trials before it ever touches a lab, and reach patients years faster. We’re building that future.
- YC batch
- F26 · Fall 2026
- Status, per YC
- Active
- Category
- AI
- Location
- San Francisco, CA, USA
- Founded
- 2026
- Checked
- 7h ago
YC tags: Health Tech, Healthcare
Changes seen
Rewrote its one-liner; it read "The full-stack AI CRO for drug discovery."
Nxtcure Labs: questions
Which YC batch was Nxtcure Labs in?
Nxtcure Labs was in Y Combinator's Fall 2026 batch (F26).
Is Nxtcure Labs still active?
Y Combinator lists Nxtcure Labs as active.
Who founded Nxtcure Labs?
Nxtcure Labs's founders, as listed on its YC page: Alessandro Hammond (Founder/CEO), Keanu Clark (Founder/CTO).
Where is Nxtcure Labs based?
Nxtcure Labs lists San Francisco, CA, USA as its location on YC's directory.